| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 645.24 | 3.1% |
| Total Income | 649.10 | 2.8% |
| Expenditure | 495.57 | 2.3% |
| PBT | 153.53 | 23.4% |
| Net Profit | 103.63 | 27.5% |
| OPM | 18.11% | 8.64pp |
| NPM | 15.95% | 3.20pp |
| EPS | 24.25 | 23.9% |
Epigral Ltd's Q3FY25 PAT jumps 110% to ₹ 104 Crore, Quarterly revenue rises 37% to ₹ 649 Crore
27 Jan 2025 · 27 Jan 2025, 07:46 pm
Summary
Epigral Ltd, a leading integrated chemical manufacturer in India, announced its financial results for the quarter ended December 31, 2024. The company's Q3FY25 PAT grew by 110% to ₹ 104 Crore, while the quarterly revenue rose by 37% to ₹ 649 Crore. The growth was primarily driven by a 15% increase in sales volume from Derivatives business and high-value products. Epigral is also expanding its CPVC Resin and Epichlorohydrin capacity, expecting volume contribution from FY2027 onwards.
Key Highlights
- 1
Epigral's Q3FY25 PAT jumps 110% to ₹ 104 Crore
- 2
Quarterly revenue rises 37% to ₹ 649 Crore
- 3
15% growth in sales volume from Derivatives business and high-value products
- 4
Expansion of CPVC Resin and Epichlorohydrin capacity
- 5
Expected volume contribution from FY2027 onwards
Informational and educational content only. Not investment advice.